logo
Treatment of Elderly Patients With Non–Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non–Small-Cell Lung Cancer: A Mini-Review
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non–Small-Cell Lung Cancer: SWOG S0533
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non–Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non–Small-Cell Lung Cancer
Factors Influencing the Diagnostic Accuracy of Identifying the Histologic Type of Non–Small-Lung Cancer With Small Samples
Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection
Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer
Diminished Disease-Free Survival After Lobectomy: Screening Implications
Maintenance or Consolidation Therapy for Non–Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects
Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma
Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC
Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non–Small-Cell Lung Cancer Cells
Long-Term Outcomes and Patterns of Failure After Surgical Resection of Small-Cell Lung Cancer
Liver Transplantation-Associated Lung Cancer: Comparison of Clinical Parameters and Outcomes
Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements
Stereotactic Body Radiotherapy for Synchronous Primary Lung Cancer: Clinical Outcome of 18 Cases
Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer With T790M Mutations
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation
Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET , ALK , and ROS1 Genomic Alterations via Comprehensive Genomic Profiling